Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04720183 | Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects | PHASE1 | COMPLETED | 8 | — | — | Jan 11, 2021 | Apr 23, 2021 | Sep 19, 2024 | 1 | United States |
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Sulfasalazine + GLPG3970 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Sulfasalazine | DRUG | On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state. |
| GLPG3970 | DRUG | On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state. |
Inclusion Criteria: * Male or female between 18 and 55 years of age (extremes included), on the date of signing the informed consent form (ICF). Females should be of non-childbearing potential. * A body mass index (BMI) between 18.0 to 30.0 kg/m2, inclusive. * A breast cancer resistance protein (BC...